On 17 June 2002, the Commission initiated proceedings in the present case and adopted a statement of objections against three addressees. The statement of objections was addressed to Rhône-Poulenc Biochimie SA, Aventis Pharma SA and Merck KgaA.
Recital 37, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002